Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Endocrine 1

Conditions

Neuroblastoma 2Pheochromocytoma 1

Interventions

Specimen Handling 265Magnetic Resonance Spectroscopy 216pembrolizumab 212Carboplatin 173Biopsy 162Cisplatin 155Nivolumab 147Cyclophosphamide 131Paclitaxel 116Radiotherapy 115Gemcitabine 110Bevacizumab 91durvalumab 84Dexamethasone 79Rituximab 74Oxaliplatin 71atezolizumab 67Fluorouracil 66Doxorubicin 65Capecitabine 65Docetaxel 64venetoclax 63Etoposide 63Radiosurgery 58Radiation 57Prednisone 55Ipilimumab 55Cytarabine 55Pemetrexed 54Lenalidomide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × 3-Iodobenzylguanidine × 90 days × Clear all
NCT00107289 2026-05-29

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
200 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

NCT00253435 2026-04-28

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 2 Completed
50 enrolled 12 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡